Minocyclin

DRUG3 trials

Sponsors

University of Southern California, State University of New York at Buffalo, Universiteit Antwerpen

Conditions

Acute Ischemic StrokeAneurysm, RupturedBlood Brain Barrier DefectDelayed Cerebral IschemiaInflammationMajor Depressive DisorderVasospasm, Intracranial

Phase 2

Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)

Active, not recruitingNCT04876638

University of Southern CaliforniaAneurysm, Ruptured, Blood Brain Barrier Defect, Delayed Cerebral Ischemia +1

Start: 2019-07-01End: 2028-12-30Target: 20Updated: 2023-02-10

Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke

WithdrawnNCT05367362

State University of New York at BuffaloAcute Ischemic Stroke

Start: 2025-12-01End: 2026-03-01Updated: 2026-03-06

Phase 3

INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder

RecruitingNCT05644301

Universiteit AntwerpenInflammation, Major Depressive Disorder

Start: 2023-09-21End: 2026-09-30Target: 240Updated: 2024-10-15

Related Papers

Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: Protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial.

2024-09-1910 citations

Minocycline decreases blood-brain barrier permeability following aneurysmal subarachnoid hemorrhage: a randomized, double-blind, controlled trial

Journal of neurosurgery2022-03-297 citations